| dc.contributor.advisor | Lawler, Mark | |
| dc.contributor.author | Spellacy, Neil | |
| dc.date.accessioned | 2017-06-28T11:06:36Z | |
| dc.date.available | 2017-06-28T11:06:36Z | |
| dc.date.issued | 2005 | |
| dc.identifier.citation | Neil Spellacy, 'An investigation into the potential use of Beta-Galactoside binding protein as a novel anti-leukaemic agent', [thesis], Trinity College (Dublin, Ireland). School of Medicine. Discipline of Haematology, 2005, pp 249 | |
| dc.identifier.other | THESIS 7607 | |
| dc.description.abstract | Chronic myelogenous leukaemia (CML) is characterised at the molecular level by a (9;22) translocation which places the abl proto-oncogene under the control of the breakpoint cluster region (bcr) gene promoter generating a fusion protein (p210) with enhanced tyrosine kinase activity. CML cells are inherently resistant to apoptosis induced by conventional chemotherapeutic agents. | |
| dc.format | 1 volume | |
| dc.language.iso | en | |
| dc.publisher | Trinity College (Dublin, Ireland). School of Medicine. Discipline of Haematology | |
| dc.relation.isversionof | http://stella.catalogue.tcd.ie/iii/encore/record/C__Rb12446076 | |
| dc.subject | Haematology and Oncology, Ph.D. | |
| dc.subject | Ph.D. Trinity College Dublin | |
| dc.title | An investigation into the potential use of Beta-Galactoside binding protein as a novel anti-leukaemic agent | |
| dc.type | thesis | |
| dc.type.supercollection | thesis_dissertations | |
| dc.type.supercollection | refereed_publications | |
| dc.type.qualificationlevel | Doctoral | |
| dc.type.qualificationname | Doctor of Philosophy (Ph.D.) | |
| dc.rights.ecaccessrights | openAccess | |
| dc.format.extentpagination | pp 249 | |
| dc.description.note | TARA (Trinity’s Access to Research Archive) has a robust takedown policy. Please contact us if you have any concerns: rssadmin@tcd.ie | |
| dc.identifier.uri | http://hdl.handle.net/2262/80517 | |
